Global Health Theme Stream
Pharmaceuticals Without Borders
The development and delivery of pharmaceutical products has become a global endeavor. Diseases and other treatable health conditions do not recognize borders, therefore it is incumbent upon the Pharmaceutical Industry to maintain a global perspective. This Theme Stream consists of three half-day sessions addressing critical needs and challenges in providing quality medicines to the entire global population.
Session 1
Pharmaceuticals without Borders: Developing New Treatments to Address the Global Burden of Disease
Infectious diseases raise awareness of our global vulnerability, the need for strong health care systems and the potentially broad and borderless-impact of disease. Prominent partnerships and initiatives against the three most devastating diseases: HIV/AIDS, tuberculosis and malaria have renewed interest in the research and development of new diagnostics, vaccines and drug treatments. This session will discuss initiatives, partnerships and approaches to address the need for increased biomedical research and pharmaceutical development for quality affordable medicines for the global community.
Session 2
Pharmaceuticals without Borders: The Regulatory and Supply Chain Challenges of Providing Medicines to Emerging Markets
Delivering Pharmaceuticals to emerging markets and underserved populations at a reasonable cost is a goal of the Pharmaceutical Industry. To realize this goal several obstacles need to be address. These include different regulatory guidance and expectations, maintaining the quality, safety and efficacy of packaging, excipients and active pharmaceutical ingredients, and controlling the stability of the pharmaceuticals during shipment. This session will discuss how these obstacles are currently being addressed and propose strategies for the future.
Session 3
Pharmaceuticals without Borders: Ensuring the Integrity and Quality of Medicines Reaching the Patient
Several events over the past few years have highlighted the devastating impact on public health when sub-standard or adulterated medicines are administered. To prevent such occurrences in the future, active measures need to be taken to ensure the quality and integrity of excipients, active pharmaceutical ingredients and manufactured drug products that enter the global pharmaceutical supply chains. This session will discuss activities initiated by global regulatory agencies and pharmaceutical industries to ensure the quality and integrity of medicines.